Coagulation and Fibrinolytic Activity in Trophoblastic Disease

  • Hiroaki Soma
  • Hirokazu Ogawa
Conference paper


Trophoblastic disease can be mainly classified into hydatidiform mole, invasive mole, and choriocarcinoma. Since uterine bleeding is the most common symptom of trophoblastic disease, some patients may experience profuse bleeding after evacuation of a hydatidiform mole and bleeding from a vaginal lesion or metastatic foci of choriocarcinoma. Hydatidiform mole is one of the obstetric conditions associated with disseminated intravascular coagulation (DIC). Despite advances in the management of trophoblastic disease, hemorrhage remains a major risk in patients with trophoblastic disease. In this report, plasma concentrations of coagulation and fibrinolytic factors measured in patients with trophoblastic disease and a case report of a patient who died of DIC following chemotherapy immediately after expulsion of the mole are presented.


Disseminate Intravascular Coagulation Disseminate Intravascular Coagulation Fibrinolytic Activity Hydatidiform Mole Molar Pregnancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Terada K (1981) Studies on hypercoagulable state and fibrinolytic activity in association with advanced gynecologic cancer. J Obstet Gynecol Neonatal Hematol 5: 179–199 (in Japanese)Google Scholar
  2. 2.
    Egley CC, Simon LR, Haddox Th (1975) Hydatidiform mole and disseminated intravascular coagulation. Am J Obstet Gynecol 121: 1122–1123PubMedGoogle Scholar
  3. 3.
    Talbert LM, Easterling WE Jr, Flowers CE Jr, Graham JB (1961) Coagulation defects of pregnancy including a case of a patient with hydatidiform mole. Obstet Gynecol 18: 69–76PubMedGoogle Scholar
  4. 4.
    Soma H, Malla D, Dali SM (1989) Clinical experience with trophoblastic diseases in Nepal. Jpn J Cancer Chemother 16: 1577–1581 (part II)Google Scholar
  5. 5.
    Goldstein, DP, Brakman P, Marshall JR (1966) The plasma fibrinolytic system in patients with trophoblastic disease and undelivered hydatidiform mole. Am J Obstet Gynecol 94: 21–28PubMedGoogle Scholar
  6. 6.
    López-Llera M, Espinosa ML, Ramos JN, Diaz de Leon M (1977) Coagulation and fibrinolysis in molar pregnancy. Am J Obstet Gynecol 127: 855–860PubMedGoogle Scholar
  7. 7.
    Tsakok FHM, Koh S, Ratnam SS (1976) Coagulation and fibrinolysis in intact hydatidiform molar pregnancy. Br Med J 2: 1481–1484PubMedCrossRefGoogle Scholar
  8. 8.
    Åstedt B, Heimburger N (1988) Spezifisches Plasminogenaktivator-inhibitoren. Hamostaseologie 8: 233–239Google Scholar
  9. 9.
    Feinberg RF, Kliman HJ, Haimowitz JE, Queenan JT, Wun T-Ch, Strauss JF III (1988) Plasminogen activator inhibitor types 1 and 2 in human trophoblast. Proceedings of the 11th Rochester Trophoblast Conference with the European Placenta Group. abstract 106Google Scholar
  10. 10.
    Åstedt B, Hagerstrand I, Lecander I (1986) Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 56: 63–65PubMedGoogle Scholar
  11. 11.
    de Jong E, Knot EAR, Divet O, Iburg AC, Rijken DC, Veenhof KHN, Dooije-waard G, ten Cate JW (1987) Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 57: 140–143PubMedGoogle Scholar

Copyright information

© Springer Japan 1991

Authors and Affiliations

  • Hiroaki Soma
    • 1
  • Hirokazu Ogawa
    • 2
  1. 1.Department of Obstetrics and Gynecology Tokyo Medical College HospitalShinjuku-ku, Tokyo, 160Japan
  2. 2.Saitama Medical SchoolSaitama PrefectureJapan

Personalised recommendations